Latest Breaking News On - Icosapent ethyl intervention - Page 1 : comparemela.com

Amarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomUnited arab emiratesNew jerseyGreat britainClin cardiolMark marmurDennis riedlColl cardiolNabil abadirExchange commissionJournal of the american college cardiologyAmerican heart associationHead of global medical affairsA report from the american heart associationAmarin corporation

Amarin Corporation plc: Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

- New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression - Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism

United statesLoyola universityNew jerseyUnited arab emiratesMark marmurColl cardiolMarkg rabbatMohamad kassabNabil abadirClin cardiolLisa defrancescoFarouc jafferAmarin pharmaceuticals irelandJournal of the american college cardiologyAmerican heart associationExchange commission

Amarin Corporation plc: Amarin Announces New REDUCE-IT® Data at ACC 23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event

Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding Analysis Builds on Consistently

United statesNew jerseyUnited kingdomUnited arab emiratesGreat britainClin cardiolColl cardiolAmerican heart associationDrug administrationExchange commissionAmarin corporationEuropean unionAmarin pharmaceuticals irelandJournal of the american college cardiologyA report from the american heart associationPost hoc analysis shows

Amarin Corporation plc: New REDUCE-IT Data Show VASCEPA/VAZKEPA (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis

United statesNew jerseyUnited kingdomUniversity of pennsylvaniaUnited arab emiratesComunidad autonoma de catalunaGreat britainClin cardiolColl cardiolMichael millerJ cardiovasc pharmacotherAmerican heart associationOral abstract at european society of cardiologyDrug administrationExchange commissionAmarin corporation

Amarin Corporation plc: New REDUCE-IT Data Show VASCEPA/VAZKEPA (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses Data Presented During Late-Breaking Science Session at European

United statesNew jerseyUnited kingdomUnited arab emiratesComunidad autonoma de catalunaGreat britainClin cardiolColl cardiolPabout amarinDeepakl bhattAmerican heart associationDrug administrationScience session at european society of cardiologyProfessor of medicine at harvard medical schoolExchange commissionClinical endpoint committee